Molecular and Cellular Biochemistry

, Volume 392, Issue 1–2, pp 145–152 | Cite as

The role of NF2 gene mutations and pathogenesis-related proteins in sporadic vestibular schwannomas in young individuals

Article

Abstract

Vestibular schwannomas (VSs) are benign tumors arising from eighth cranial nerve and most often occur sporadically in individuals of middle age group. Sporadic VSs are rarely reported in the young population. In this study, we evaluated clinical behaviors of 12 young sporadic VSs by the statistical comparison with a matched series of 145 adult cases. We found that young tumors were characterized by an earlier onset of initial symptom, shorter duration from the first symptom to diagnosis, and larger tumor size than adult ones. Standard sequencing demonstrated the presence of NF2 mutations in eight tumors. All NF2 mutations identified were truncating mutations (nonsense, frameshift, and splicing-site mutations). Earlier formation of VSs in young patients was evidenced by the high incidence of NF2 mutations (66.7 %) far beyond our previous study in the adult case series (34.5 %). Furthermore, young tumors exhibited deficient merlin or heightened phosphorylated merlin that was subsequently demonstrated to be well correlated with increased tumor size. Finally, we compared protein levels of four pathogenesis-related molecules between young and adult group but there was no significant difference. These results led us to suggest that high frequency of NF2 mutations may play a critical role in early tumorigenesis of young VSs. Moreover, merlin deficiency or phosphorylation status of merlin was involved in their earlier development. Further study remains to fully understand the mechanism for the rapid growth of young VSs.

Keywords

Vestibular schwannomas Young patients NF2 gene Mutation Merlin 

References

  1. 1.
    Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis and neurofibromatosis 2. JAMA 278:51–57PubMedCrossRefGoogle Scholar
  2. 2.
    Jacoby LB, MacCollin M, Louis DN et al (1994) Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 3:413–419PubMedCrossRefGoogle Scholar
  3. 3.
    Cayé-Thomasen P, Borup R, Stangerup SE et al (2010) Deregulated genes in sporadic vestibular schwannomas. Otol Neurotol 31:256–266PubMedCrossRefGoogle Scholar
  4. 4.
    Ahmad Z, Brown CM, Patel AK et al (2010) Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumor genesis. Otol Neurotol 31:460–466PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Hadfield KD, Smith MJ, Urquhart JE et al (2010) Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29:6216–6221PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang Zhihua, Wang Zhaoyan, Sun Lianhua et al (2013) Mutation spectrum and differential gene expression in cystic and solid vestibular schwannoma. Genet Med. doi:10.1038/gim.2013.114 Google Scholar
  7. 7.
    Bretscher A, Edwards K, Fehon RG et al (2002) Proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586–599PubMedCrossRefGoogle Scholar
  8. 8.
    Li W, You L, Cooper J, Schiavon G et al (2010) Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4 DCAF1 in the nucleus. Cell 140:477–490PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    James MF, Han S, Polizzano C et al (2010) NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29:4250–4261CrossRefGoogle Scholar
  10. 10.
    Lallemand D, Manent J, Couvelard A et al (2009) Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 28:854–865PubMedCrossRefGoogle Scholar
  11. 11.
    Hamaratoglu F, Willecke M, Kango-Singh M et al (2006) The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8:27–36PubMedCrossRefGoogle Scholar
  12. 12.
    Okada T, Lopez-Lago M, Giancotti FG (2006) Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 171:361–371CrossRefGoogle Scholar
  13. 13.
    Rong R, Surace EI, Haipek CA et al (2004) Serine 518 phosphorylation modulates merlin intramolecular as sociation and binding to critical effectors important for NF2 growth suppression. Oncogene 23:8447–8454PubMedCrossRefGoogle Scholar
  14. 14.
    Jin H, Sperka T, Herrlich P et al (2006) Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 442:576–579PubMedCrossRefGoogle Scholar
  15. 15.
    Yang C, Asthagiri AR, Iyer RR et al (2011) Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci USA 108:4980–4985PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Walcott BP, Sivarajan G, Bashinskaya B et al (2009) Sporadic unilateral vestibular schwannoma in the pediatric population. J Neurosurg Pediatr 4:125–129PubMedCrossRefGoogle Scholar
  17. 17.
    House JW, Brackmann DE (1985) Facial nerve grading system. Otolaryngol Head Neck Surg 93:146–147PubMedGoogle Scholar
  18. 18.
    Wu H, Chen Y, Wang ZY et al (2010) Involvement of p21 (waf1) in merlin deficient sporadic vestibular schwannomas. Neuroscience 170:149–155PubMedCrossRefGoogle Scholar
  19. 19.
    Wang Zhaoyan, Yanjun Lu, Tang Juanjuan et al (2009) The phosphorylation status of merlin in sporadic vestibular Schwannomas. Mol Cell Biochem 324:201–206PubMedCrossRefGoogle Scholar
  20. 20.
    Dayalan AH, Jothi M, Keshava R et al (2006) Age dependent phosphorylation and deregulation of p53 in human vestibular schwannomas. Mol Carcinog 45:38–46PubMedCrossRefGoogle Scholar
  21. 21.
    Xiao GH, Gallagher R, Shetler J et al (2005) The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25(6):2384–2394PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Kim H, Kwak NJ, Lee JY et al (2004) Merlin neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 279:7812–7818PubMedCrossRefGoogle Scholar
  23. 23.
    Lasak JM, Welling DB, Akhmametyeva et al (2002) Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas. Laryngoscope 112:1555–1561PubMedCrossRefGoogle Scholar
  24. 24.
    Propp JM, McCarthy BJ, Davis FG et al (2006) Descriptive epidemiology of vestibular schwannomas. Neuro Oncol 8:1–11PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Neary W, Newton VE, Laiode-Kemp SN et al (1996) A clinical, genetic and audiological study of patients with unilateral vestibular schwannomas. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas. J Laryngol Otol 110:634–640PubMedGoogle Scholar
  26. 26.
    Evans DGR, Lye R, Neary W et al (1999) Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J Neurol Neurosurg Psychiatry 66:764–767PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Matthies C, Samii M (1997) Management of 1000 vestibular schwannomas (Acoustic Neuromas): clinical presentation. Neurosurgery 40:1–10PubMedGoogle Scholar
  28. 28.
    Mirzayan MJ, Gerganov VM, Lüdemann W et al (2007) management of vestibular schwannomas in young patients-comparison of clinical features and outcome with adult patients. Childs Nerv Syst 23:891–895PubMedCrossRefGoogle Scholar
  29. 29.
    Torres-Martin M, Lassaletta L, San-Roman-Montero J et al (2013) Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation. Int J Oncol 42:848–862PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Otolaryngology Head and Neck Surgery, Xinhua HospitalSchool of Medicine, Shanghai Jiao Tong UniversityShanghaiChina
  2. 2.Ear InstituteSchool of Medicine, Shanghai Jiao Tong UniversityShanghaiChina

Personalised recommendations